Earnings summaries and quarterly performance for Immunome.
Executive leadership at Immunome.
Clay Siegall
Detailed
President and Chief Executive Officer
CEO
BL
Bob Lechleider
Detailed
Chief Medical Officer
JH
Jack Higgins
Detailed
Chief Scientific Officer
KH
Kinney Horn
Detailed
Chief Business Officer
MR
Max Rosett
Detailed
Chief Financial Officer
PT
Phil Tsai
Detailed
Chief Technical Officer
RS
Roee Shahar
Detailed
Executive Vice President, Commercial
SS
Sandra Stoneman
Detailed
Chief Legal Officer and General Counsel
Board of directors at Immunome.
Research analysts covering Immunome.
Recent press releases and 8-K filings for IMNM.
Immunome Provides Pipeline Update at J.P. Morgan Healthcare Conference
IMNM
New Projects/Investments
Product Launch
Guidance Update
- Immunome reported positive top-line data for its oral drug, AL102, a gamma-secretase inhibitor for desmoid tumors, in December, achieving a hazard ratio of 0.16, 56% objective response rate, and 83% median tumor reduction. The company plans to submit the New Drug Application (NDA) for AL102 in the second quarter of 2026.
- The company's ROR1 ADC (IM-1021) has demonstrated objective responses at multiple dose levels in Phase I clinical trials, leading to expanded trial sites, with clinical data anticipated to be released this year.
- Immunome's pipeline includes a FAP radioligand, which has been cleared by the FDA to begin clinical trials within the next couple of months, and the company plans to submit three Investigational New Drug (IND) applications for solid tumor ADCs in 2026 and three more in 2027.
- The company maintains a strong cash position, with funds projected to last into 2028.
1 day ago
Immunome Provides Update on Oncology Pipeline and Milestones
IMNM
Product Launch
New Projects/Investments
Guidance Update
- Immunome plans to submit a New Drug Application (NDA) for Varegacestat in 2Q 2026, following positive Phase 3 topline data for desmoid tumors, which demonstrated a Progression-Free Survival Hazard Ratio of 0.16 (p<0.0001) and a Confirmed Objective Response Rate of 56%.
- The company is advancing a deep ADC pipeline, including IM-1021 (ROR1 ADC) with initial lymphoma data expected in 2026, and three first-in-class solid tumor ADCs (IM-1617, IM-1340, IM-1335) with Investigational New Drug (IND) submissions planned for Early, Mid, and Late 2026, respectively.
- Immunome's IM-3050 FAP Radiotherapy is entering Phase 1, with the First Patient In expected Early 2026.
- The company's financial runway is expected to extend into 2028.
1 day ago
Immunome Highlights Positive AL102 Data and Pipeline Expansion at J.P. Morgan Conference
IMNM
Product Launch
New Projects/Investments
Guidance Update
- Immunome reported positive top-line data for its AL102 (varegacestat) program for desmoid tumors in December. Key results include an objective response rate of 56% and a median tumor reduction of 83%. The company plans to submit a New Drug Application (NDA) for AL102 in the second quarter of this year (2026) and anticipates potential approval this calendar year.
- The company's ROR1 ADC (IM-1021) has demonstrated objective responses at multiple dose levels in Phase 1 clinical trials for B lymphomas, leading to an expansion of clinical sites. Immunome also has a FAP radioligand that has received FDA clearance and is expected to start clinical trials within the next couple of months.
- Immunome plans significant pipeline expansion, aiming to submit three Investigational New Drug (IND) applications this year (2026) and three for next year (2027), all targeting solid tumors with its advanced ADC platform.
- The company maintains a strong financial position, with enough cash projected to extend into 2028.
1 day ago
Immunome Provides Pipeline Update and AL102 NDA Submission Timeline at J.P. Morgan Healthcare Conference
IMNM
Product Launch
New Projects/Investments
Guidance Update
- Immunome reported positive top-line data in December for AL102 (varegacestat), an oral gamma-secretase inhibitor for desmoid tumors, demonstrating a hazard ratio of 0.16, an objective response rate of 56%, and a median tumor reduction of 83%. The company plans to submit a New Drug Application (NDA) for AL102 in the second quarter of 2026.
- The company's ROR1 ADC (IM-1021) has shown objective responses at multiple dose levels in Phase 1 clinical trials for B lymphomas, with clinical data expected to be released this year. Immunome is also expanding its ADC pipeline with three new solid tumor ADC INDs planned for 2026 and three for 2027.
- Immunome's FAP radioligand has been cleared by the FDA and is expected to start clinical trials within the next couple of months.
- The company maintains a strong cash position that extends into 2028. By the end of 2026, Immunome anticipates potentially having seven drugs in clinical development and one drug on the market.
1 day ago
Immunome Announces Pricing of Public Offering of Common Stock
IMNM
- Immunome, Inc. (IMNM) priced an underwritten public offering of 18,625,000 shares of its common stock at $21.50 per share.
- The offering is expected to generate approximately $400 million in gross proceeds for Immunome.
- Underwriters have a 30-day option to purchase up to an additional 2,793,750 shares of common stock.
- The offering is anticipated to close on December 18, 2025.
Dec 17, 2025, 1:16 AM
Immunome Announces Proposed Public Offering of Common Stock
IMNM
- Immunome, Inc. announced a proposed underwritten public offering to issue and sell $400 million of its common stock.
- The company expects to grant the underwriters a 30-day option to purchase up to an additional $60 million of shares of common stock.
- The proposed offering is being made pursuant to a shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on February 13, 2024.
- Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.
Dec 15, 2025, 9:01 PM
Immunome announces positive Phase 3 Ringside trial results for AL102 in desmoid tumors
IMNM
Product Launch
New Projects/Investments
- Immunome reported positive top-line results from its Ringside phase 3 study of AL102 for desmoid tumors, with the trial meeting all primary and secondary endpoints.
- Key efficacy data for AL102 include a progression-free survival (PFS) hazard ratio of 0.16, an objective response rate (ORR) of 56%, and a median best tumor volume reduction of 83%.
- AL102, an oral gamma secretase inhibitor, demonstrated a manageable safety profile consistent with its drug class and is positioned as a potential best-in-class treatment.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026.
- The company is advancing commercial preparations to target the approximately 11,000 actively managed desmoid tumor patients in the U.S..
Dec 15, 2025, 1:30 PM
Immunome Announces Positive Phase 3 Results for Varegacestat in Desmoid Tumors
IMNM
Product Launch
New Projects/Investments
- Immunome reported positive top-line results from its Phase 3 Ringside trial for varegacestat, an oral gamma secretase inhibitor, in patients with progressing desmoid tumors, meeting all primary and secondary endpoints.
- Key efficacy outcomes include a progression-free survival (PFS) hazard ratio of 0.16 (representing an 84% reduction in disease progression risk), a confirmed objective response rate (ORR) of 56%, and a median best percentage reduction of tumor volume of 83%.
- Varegacestat was generally well tolerated with a manageable safety profile, showing a 55.6% ovarian toxicity rate in women of childbearing potential, which is lower than the up to 75% reported for the GSI class.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026, with commercial preparations on track for launch.
Dec 15, 2025, 1:30 PM
Immunome Announces Positive Phase 3 Ringside Trial Results for AL102
IMNM
Product Launch
New Projects/Investments
- Immunome's AL102 met all primary and secondary endpoints in the Phase 3 Ringside trial for progressing desmoid tumors, demonstrating a 0.16 progression-free survival (PFS) hazard ratio, a 56% confirmed objective response rate (ORR), and an 83% median best percentage reduction of tumor volume.
- AL102 was generally well tolerated with a manageable safety profile consistent with the GSI class, with common adverse events including diarrhea, fatigue, rash, nausea, and cough, mostly grade one or two.
- Immunome plans to meet with the FDA in early 2026 and submit a New Drug Application (NDA) in the second quarter of 2026.
- The company aims to establish AL102 as the standard of care for desmoid tumors, focusing commercial efforts on approximately 85 specialty sarcoma centers in the U.S. and expecting greater than 90% payer coverage at launch.
Dec 15, 2025, 1:30 PM
IMNM Announces Positive Topline Results for Varegacestat Phase 3 RINGSIDE Study
IMNM
Product Launch
New Projects/Investments
- IMNM's Varegacestat achieved its primary and all key secondary endpoints in the RINGSIDE Phase 3 study for Desmoid Tumors, demonstrating a Progression-Free Survival hazard ratio of 0.16 (p<0.0001) and a 56% Confirmed Objective Response Rate.
- The study showed an 84% reduction in the risk of progression or death versus placebo and a median best tumor volume reduction of 83% with Varegacestat.
- Varegacestat was generally well-tolerated with a manageable safety profile, although 55.6% of premenopausal women experienced ovarian toxicity.
- An NDA submission for Varegacestat is planned for 2Q 2026, with the company positioning it to become the Standard of Care in Desmoid Tumors due to its best-in-class results.
Dec 15, 2025, 1:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more